CoChat

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

Open access
Botticelli, Andrea, Zizzari, Ilaria, Mazzuca, Federica, Ascierto, Paolo Antonio, Putignani, Lorenza, Marchetti, Luca, Napoletano, Chiara, Nuti, Marianna, Marchetti, Paolo · 2017 · Oncotarget
Cited by 56

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

// Andrea Botticelli 2,* , Ilaria Zizzari 1,* , Federica Mazzuca 2 , Paolo Antonio Ascierto 4 , Lorenza Putignani 3 , Luca Marchetti 5 , Chiara Napoletano 1 , Marianna Nuti 1,* and Paolo Marchetti 2,* 1 Department of Experimental Medicine, “Sapienza University of Rome, Rome, Italy 2 Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, Italy 3 Units of Parasitology and Human Microbiome, Bambino Gesù Children’s Hospital and Research Institute, Rome, Italy 4 Melanoma, Cancer Immunotherapy, and Innovative Therapy, Istituto nazionale Tumori Fondazione “G Pascale”, Napoli, Italy 5 Department of Clinical Oncology, Policlinico Umberto I, University of Rome Sapienza, Rome, Italy Correspondence to: Marianna Nuti, email: // * These authors have contributed equally to this work Keywords : microbiome, immunotherapy, PD-1, PDL-1, CTLA-4 Received : July 18, 2016 Accepted : October 13, 2016 Published : October 28, 2016 Abstract Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity. In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12985

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 56

Metadata

Authors
Botticelli, A., Zizzari, I., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P.
Venue
Oncotarget
Published
2016-10-28
Volume
8
Issue
5
Pages
8890-8899
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2545600439
Cited by
56
References
24
FWCI
4.33
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. https://app.cochat.ai/papers/10.18632/oncotarget.12985
The paper
Botticelli, A., Zizzari, I., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P. (2017). Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget. https://doi.org/10.18632/oncotarget.12985

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.